title: The year in cardiology 2016: prevention.
authors.affiliation: Heart Failure Unit, Cardiology, G da Saliceto Hospital, AUSL Piacenza, Piacenza, 29121, Italy.
authors.forename: Massimo F
authors.initials: MF
authors.lastname: Piepoli
authors.affiliation: Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Taddei
authors.affiliation: Klinik für Innere Medizin III, IMED 41.1; UdS; Universität des Saarlandes, Homburg, 66421, Germany.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Laufs
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000187:drug effects; D003925:Diabetic Angiopathies / Q000517:prevention & control; D000072001:Diet, Healthy; D050171:Dyslipidemias / Q000517:prevention & control; D004777:Environment; D000070497:Healthy Lifestyle; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006973:Hypertension / Q000517:prevention & control; D009765:Obesity / Q000517:prevention & control; D000091362:PCSK9 Inhibitors; D016540:Smoking Cessation; D000071449:Proprotein Convertase 9
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000091362:PCSK9 Inhibitors; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9